REGENXBIO Inc. (RGNX)
NASDAQ: RGNX
· Real-Time Price · USD
8.57
-0.09 (-1.04%)
At close: Jun 18, 2025, 3:59 PM
8.55
-0.31%
After-hours: Jun 18, 2025, 05:35 PM EDT
-1.04% (1D)
| Bid | 8.4 |
| Market Cap | 430.12M |
| Revenue (ttm) | 156.72M |
| Net Income (ttm) | -157.69M |
| EPS (ttm) | -3.09 |
| PE Ratio (ttm) | -2.78 |
| Forward PE | -6.05 |
| Analyst | Buy |
| Ask | 9.4 |
| Volume | 836,170 |
| Avg. Volume (20D) | 1,157,612 |
| Open | 8.57 |
| Previous Close | 8.66 |
| Day's Range | 8.51 - 8.98 |
| 52-Week Range | 5.04 - 15.36 |
| Beta | 1.09 |
About RGNX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RGNX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RGNX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
-17.06%
Regenxbio shares are trading lower after the compa...
Unlock content with
Pro Subscription
1 month ago
+2.63%
RGNX stock has given up its prior gain. Regenxbio shares were trading higher following Q1 financial results and after the company announced FDA acceptance and priority review of BLA for RGX-121.
